Cytek IPO Presentation Deck

1. 2 3. Cytek is Becoming the Premier Cell Analysis Company Novel, patented FSP platform utilizes the full spectrum of fluorescent signatures to deliver high-resolution, high-content and high-sensitivity cell analysis ***** Cli 111FE K 8 88 Highly intuitive, integrated workflow solutions driving strong adoption with over 750 instruments placed since commercial launch in 2017 Validated platform with over 210 peer-reviewed publications, which continues to accelerate alongside growing applications Delivering rare combination of high revenue growth (60% YoY¹) with profitability (16% Adjusted EBITDA margins2,3) Potential utility across a myriad of research and clinical applications could allow Cytek to access the broader $23Bn cell analysis market4 Comprehensive suite of solutions expands customer base and diversification, and provides recurring revenue opportunity Revenue growth between FY2019-FY2020 We define Adjusted EBITDA as net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for (benefit from) income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses. Adj. EBITDA Margin is on a percentage of revenue basis Reconciliation of Non-GAAP figures are in the appendix 2024 market pmiection estimate s CYTEK

View entire presentation